Impact of Antimicrobial Stewardship Program
|ClinicalTrials.gov Identifier: NCT04039152|
Recruitment Status : Recruiting
First Posted : July 31, 2019
Last Update Posted : July 21, 2020
|Condition or disease||Intervention/treatment|
|Blood Stream Infections||Other: Clinical pharmacists recommendations to optimize antibiotics use|
- The Ultimate aims of antimicrobial stewardship program are to improve antimicrobials efficacy, minimize their adverse effects and limit antimicrobial resistance.
- The aim of this study is to measure the clinical & economic impact of antimicrobial stewardship program interventions.
• Prospective-audit with feedback program strategy (Single-center, prospective, pre- and post-intervention study).
• This study will be conducted in Neonatal Intensive Care Unit of Assiut University Children's Hospital, Assiut University, Assiut, Egypt.
• 12- 18 months.
• This study approved by the University Ethics Medical Committee. Informed consent is unnecessary since antimicrobial stewardship program interventions represent a part of routine clinical practice. Patients records will be identified by coded numbers to maintain privacy.
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||Impact of Antimicrobial Stewardship Program on Antibiotics Use in Neonatal Intensive Care Unit at Assiut University Children's Hospital|
|Actual Study Start Date :||January 1, 2019|
|Estimated Primary Completion Date :||October 31, 2020|
|Estimated Study Completion Date :||December 31, 2020|
Pre- interventions group
Without clinical pharmacists recommendations to optimize antibiotics use
Post - interventions group
interventions include clinical pharmacists recommendations to optimize antibiotics use
Other: Clinical pharmacists recommendations to optimize antibiotics use
Optimal dosing, drug bug mismatch
- Mortality rate in each group [ Time Frame: 18 month ]Number of deaths
- Average Length of hospital stay in each group [ Time Frame: 18 month ]In days
- Total Antibiotics consumption [ Time Frame: 18 month ]in the form of defined daily doses
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04039152
|Contact: Neveen Abdelaalfirstname.lastname@example.org|
|Assiut, Egypt, 71511|
|Contact: Neveen Abdelaal 00201005647073 email@example.com|